Document is current

Article History

Received: 8 February 2022

Accepted: 15 May 2022

First Online: 23 May 2022

Declarations

:

: Both the prospective study protocol (ClinicalTrials.gov Identifier: NCT04410263, BASEC ID: ZH 2020-00646) and the post hoc analysis protocol (BASEC ID: ZH 2021-01617) were approved by the Swiss regional cantonal ethical commission. The study complies with the Declaration of Helsinki, the Guidelines on Good Clinical Practice (GCP-Directive) issued by the European Medicines Agency, the Swiss law and Swiss regulatory authority requirements. Written informed consent for participation from the patient or in case of death or disability, from the next of kin or legal representative, was sought for every patient included into the study.

: Written informed consent for publication from the patient or in case of death or disability, from the next of kin or legal representative, was sought for every patient included into the study.

: The authors declare no conflicts of interest.